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Abstract Ornithine transcarbamylase (OTC) deﬁciency
is an X-linked urea cycle defect. While hemizygous males
typically present with hyperammonemic coma in infancy,
reports of rare late-onset presentations exist, with poor
outcomes in males up to 58 years old. Relatives with
mutations identical to affected patients often remain
asymptomatic, and it is likely that environmental and
genetic factors inﬂuence disease penetrance and expres-
sion. Here, we present our investigation of a patient with
late-onset presentation, and we emphasize the potential
role of environmental and genetic factors on disease
expression. The patient was a previously healthy 62-year-
old man who developed mental slowing, refractory
seizures, and coma over an 8-day period. Interestingly, the
patient had recently used home gardening fertilizers and
pesticides. Evaluations for drug and alcohol use, infections,
and liver disease were negative. Despite aggressive ther-
apy, blood NH3 concentration peaked at 2,050 lM and the
patient died from cerebral edema and cerebellar herniation.
Analysis of the OTC gene showed a Pro-225-Thr (P225T)
change in exon 7, a mutation that has been previously
implicated in OTC deﬁciency. This case illustrates that
OTC deﬁciency can cause acute, severe hyperammonemia
in a previously healthy adult and that the P225T mutation
can be associated with late-onset OTC deﬁciency. We
speculate that exposure to organic chemicals might have
contributed to the onset of symptoms in this patient. This
case also emphasizes that persistent hyperammonemia
may cause irreversible neurologic damage and that after the
diagnosis of hyperammonemia is established in an acutely
ill patient, certain diagnostic tests should be performed to
differentiate between urea cycle disorders and other causes
of hyperammonemic encephalopathy.
Keywords Hyperammonemia  OTC 
Ornithine transcarbamylase  Urea cycle  Late onset
Introduction
Ornithine transcarbamylase (OTC) deﬁciency (OMIM
311250), an X-linked disorder, is the most commonly
inherited defect of the urea cycle. While hemizygous
males typically present with hyperammonemic coma in the
neonatal period, unusual cases have been reported with
late-onset presentations in patients up to 58 years old, often
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shown that many relatives of these probands carry identical
mutations but remain asymptomatic. It is likely that genetic
and environmental factors exist that contribute to disease
manifestations in some hemizygotes, while protecting
others.
Here, we present the case of a previously healthy 62-
year-old man who developed mental slowing, refractory
seizures, and coma over an 8-day period because of
undiagnosed OTC deﬁciency. This case illustrates that
urea cycle defects can present in adulthood and can be
fatal. Acute neurologic decline and hyperammonemia in
a previously healthy adult should be investigated and
managed with this consideration in mind. Our investi-
gation of this patient bears on the potential roles of
genetic and environmental factors in the onset of disease
expression.
Methods
Ammonia analysis
Free-ﬂowing blood was collected by venipuncture into a
lithium heparin tube placed on ice and was immediately
analyzed by spectrophotometric and kinetic (glutamate
dehydrogenase) means. No hemolysis was noted on any
specimens and most were repeated to conﬁrm initial
measurements.
Orotic acid analysis
Urine specimen was collected and frozen for shipment to
the laboratory at the Children’s Hospital of Los Angeles.
Stable isotope dilution was performed and the sample was
analyzed by tandem mass spectrometry.
OTC mutation analysis
A sample from the patient’s liver was ﬂash frozen and sent
to the University of Minnesota laboratory. Genomic DNA
was extracted and PCR ampliﬁcation of all 10 exons and
exon/intron borders was performed. SSCP analysis was
used to screen for abnormal mobility of the ampliﬁed gene
fragments and sequencing of the abnormally migrating
exons was performed.
Blood gas analysis
Standard blood gas analysis was performed on arterial
blood.
Clinical diagnosis
The Glasgow coma scale, clinical observation of pupil
dilation, arm and leg movements, cough and gag reﬂexes,
and electroencephalogram for seizure activity were used
to determine the clinical status of the patient. Cerebral
edema and cerebellar herniation were observed on com-
puted tomographic scan and brain magnetic resonance
imaging and conﬁrmed by autopsy.
Case report
A previously healthy, intelligent 62-year-old man devel-
oped mental slowing, visual changes, emesis, refractory
seizures, and coma over an 8-day period. History and
physical evaluation were negative for drug or alcohol use,
infection, or liver disease. Of note, the patient had recently
used several home-gardening products for the ﬁrst time,
including fertilizers, pesticides, and sealants, and he had
dry cracked hands and did not wear gloves.
The initial blood ammonia level was elevated at 314 lg/
dl (normal range [nl] = 17–80) and rapidly rose to
2,050 lM (nl = 11–35). The urine orotic acid level was
markedly elevated at 473 mmol/mol creatinine (nl = 0–3).
The plasma citrulline level was normal at 18 lM/L
(nl = 12–55). Sodium benzoate, sodium phenylacetate,
arginine free base, lactulose, intravenous glucose, and he-
modialysis were initiated and the ammonia level gradually
dropped to 218 lM. However, the patient developed
cerebral edema and died because of cerebellar herniation,
severe hypotension, and multisystem organ failure (con-
ﬁrmed by autopsy).
Results
Mutation analysis of the OTC gene showed a single base
change (CCG ? ACG) in exon 7, leading to the substi-
tution of a threonine for a proline at position 225 (Pro-225-
Thr, P225T).
After learning of the proband’s diagnosis, several family
members underwent mutation analysis for the P225T sub-
stitution. One uncle, two brothers, and one great-nephew
were found to be hemizygous for the mutation (Fig. 1). The
six daughters of the hemizygous brothers were obligate
heterozygotes for the mutation. None of these 10 family
members, ranging in age from 2 to 96 years, has received
pharmacologic or dietary treatment. They have remained
asymptomatic with normal cognition and good health. The
male relatives have had their orotic acid and ammonia
levels checked, and these have been found to be within the
normal range.
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More than 230 disease-causing OTC mutations have
been identiﬁed, many of which are unique to the families
in which they occur [2]. In general, mutations that
affect amino acids in the interior of the enzyme near the
active site—such as proline-225—cause neonatal disease,
whereas mutations affecting residues on the surface of the
protein are associated with milder phenotypes or later onset
of disease [1]. However, in some cases, mutations that
affect the catalytic function of the mutant enzyme are
associated with late-onset disease. In particular, this report
demonstrates that OTC deﬁciency resulting from the
P225T mutation can cause such late-onset disease.
The proline-225 residue affected in this patient is con-
served among many species and may be involved in the
processing of the OTC protein [3]. Different amino acid
substitutions at proline-225 can have substantially differ-
ent disease presentations. For example, Pro-225-Arg [3]
and Pro-225-Leu [4] have been found in males with severe
neonatal OTC deﬁciency. The P225T mutation has been
documented in one other patient, a previously healthy boy
who manifested late-onset disease at 8 years of age [5].
In a stable isotope study of ureagenesis, this particular
mutation resulted in a 42% reduction in
15N incorporation
into urea, indicating that P225T allows for signiﬁcant
residual OTC activity [6].
A variety of genetic and environmental factors exist
that can lead a previously healthy hemizygote to become
acutely ill later in life. Some late-onset mutations, such as
R40H, have been shown to affect posttranslational pro-
cessing events such as targeting to the mitochondrion [1].
Several environmental factors may also contribute to the
timing of disease onset and disease manifestations. These
factors include high-protein diets, valproic acid treatment,
and exposure to the insect repellant N,N-diethyltoluamide
[7–9]. Electron microscopic studies of the liver of a late-
onset OTC patient revealed mitochondrial abnormalities
beyond those expected with OTC deﬁciency per se,
suggesting primary mitochondrial injury by exogenous
agents [10]. Organophosphates, such as the pesticides to
which this patient was exposed to, have been reported to
induce apoptosis by disrupting mitochondrial membranes
and activating caspases [11]. Our patient was in good
health until 62 years of age, when he became acutely ill
and died. In the days preceding his illness, he worked with
several home-gardening products, including pesticides,
fertilizers, and sealants. We speculate that exposure to
organic chemicals may have contributed to the onset of
symptoms in this patient; that is, chemicals may have
entered his system through his lungs or skin, accumulated
in his liver, and compromised his OTC function.
The differential diagnosis of hyperammonemia in an
older child or adult can be addressed by routine labora-
tory testing. Causes of hyperammonemia include both
nongenetic (acquired) and genetic etiologies, and include
postviral aspirin-induced Reye syndrome; acute or chronic
hepatitis; Wilson disease; a1-antitrypsin deﬁciency;
alcoholic cirrhosis; drug-induced liver failure (e.g., anti-
convulsants); chemotherapy; infection; and late-onset urea
OTC hemizygote, symptomatic
OTC hemizygote, asymptomatic
Negative test result
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Fig. 1 Pedigree of family
presented in case report. Index
patient is represented by black
square
392 Hepatol Int (2008) 2:390–394
123cycle defects. In a patient with hyperammonemia, a com-
plete blood cell (CBC) count, serum electrolytes (including
measurement of the anion gap), blood pH, blood glucose,
liver function chemistries, and urinalysis can be helpful. In
this case, a respiratory alkalosis was the only abnormality
found initially on laboratory analysis (Table 1). Speciﬁ-
cally, a normal anion gap existed, liver functions and
CBC were normal, and blood glucose (145 mg/dl) and
urinalysis (trace ketones) were near normal values. As a ﬁrst
approximation, hyperammonemia in the presence of normal
liver function and a respiratory alkalosis is highly sugges-
tive of a urea cycle defect. Additional tests are needed to
determine which urea cycle defect is present, and this
additional testing includes measurement of quantitative
plasma amino acids and urine orotic acid.
Treatment guidelines for hyperammonemia include the
following:
• Intravenous hydration with glucose and lipids to
minimize protein catabolism and endogenous ammonia
production.
• Cessation of protein intake from all sources to restrict
nitrogen intake.
• Administration of arginine HCl or arginine free base for
all urea cycle defects except arginase deﬁciency. This
allows the urea cycle to partially proceed with removal
of some fraction of accumulated nitrogen.
• Administration of compounds that facilitate the
removal of ammonia through alternate pathways,
including oral sodium phenylbutyrate, which conju-
gates glutamine, leading to the removal of two
nitrogens as phenylacetylglutamine, and oral sodium
benzoate, which conjugates glycine, leading to removal
of 1 nitrogen as hippurate. These can be given orally or,
in more severe presentations, combined in an intrave-
nous formulation.
• Hemodialysis can be performed in severe cases marked
by refractory hyperammonemia or encephalopathy, or
when there is clinical deterioration.
• Treatment of shock, sepsis, seizures, and increased
intracranial pressure.
The family members of the patient presented here raise an
important clinical issue: when and whether to treat
asymptomatic individuals with OTC mutations, given an
index patient with late-onset disease [12]. In this case, we
elected close clinical monitoring of the affected relatives,
although a more aggressive approach may be warranted.
Female carriers should be followed in addition to males.
Asymptomatic family members can opt for diet modi-
ﬁcation and prophylactic urea cycle defect therapy, but it is
unclear whether these measures are necessarily more
effective than close clinical monitoring in the prevention of
hyperammonemia and metabolic decompensation.
Treatment possibilities for asymptomatic family mem-
bers include:
• Carrying an emergency letter indicating that they are at
risk of hyperammonemia. Included in the letter should
be the laboratory testing to be obtained, the contact
number of a metabolic specialist, and instructions for
the dose and administration of arginine, sodium ben-
zoate, and sodium phenylacetate.
• Monitoring of blood ammonia levels during intercur-
rent illnesses to determine whether ammonia levels are
Table 1 Serial laboratory values of patient
Ammonia pH pCO2 HCO3 AST ALT Orotic acid Therapeutics for
hyperammonemia
Date/normal
range
11–35 lmol/l 7.35–7.45 35–45 21–27 12–42 U/l 9–50 U/l 0–3 mmol/mol
creatinine
Day 1
a 314 7.47 33 24 22 33 nd Lactulose
Day 4
a 203 nd nd nd nd nd nd Lactulose
Day 5
a 183 7.5 29 23 24 36 nd Lactulose
Day 6, 0635 457 7.6 20.1 20 28 34 nd Lactulose, Sodium Benzoate,
Phenylacetate
Day 6, 2150 1345 7.3 50.6 24.3 nd nd nd
Day 7, 0330 1240 7.44 33.1 22.2 nd nd nd Lactulose, Sodium Benzoate,
Phenylacetate, Arginine free base
Day 7, 0930 2050 7.45 33 22.6 nd nd nd
Day 7, 1210 1269 nd nd nd nd nd 473 CVVHD started
Day 8, 1151 218 7.14 29.5 9.5 nd nd nd Lactulose, Sodium Benzoate,
Phenylacetate, Arginine free base
a Labs done at outside hospital prior to transfer; CVVHD-continuous veno-venous hemodialysis
nd—not done
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123elevated during catabolic stress. If elevations occur, an
emergency interval diet plan can be provided for ﬂuid
and nutritional requirements, including cessation of
protein intake and provision of adequate calories.
• Ongoing dietary restriction of protein and supplemen-
tation with an essential amino acid formula.
In conclusion, it is important to recognize that acute
neurologic decline and hyperammonemia in a previously
healthy adult may be due to a urea cycle defect (Table 2).
Vigilance by clinicians can lead to rapid treatment and
appropriate involvement of metabolic specialists. Finally,
molecular studies in patients such as the one in this report
will help identify genotype–phenotype correlations and
contribute to our understanding of disease mechanisms in
this heterogenous disorder.
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Table 2 Neurologic status of patient
Pupils R/L Glascow coma scale Arm movement R/L Leg movement R/L Seizures Gag reﬂex Cough reﬂex
Day 1
a Eyes
b, Motor 5, Verbal 4 Spontaneous Spontaneous None Present Present
Day 5 3/3.5 brisk Eyes 1, Motor 4, Verbal 1
c Flexion/extension Trace voluntary None Present Present
Day 6 5/5 no rxn Eyes 1, Motor 1, Verbal 1 No movement No movement Present None None
Day 7 7.5/8 no rxn Eyes 1, Motor 1, Verbal 1 No movement No movement Present None None
Day 8 4.5/4.5 ﬁxed Eyes 1, Motor 1, Verbal 1 No movement No movement None None None
a Outside hospital reported equal and reactive to light
b Preferred to keep eyes closed but would sometimes open to speech (3), usually only to pain (2)
c Endotracheal tube was placed on day 2
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